In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|February 2, 2021
ApiJect Appoints New Leadership Advisory Board
Author(s)BioPharm International Editors
The new board will join the company’s co-founder and chairman, Jay Walker, and company CEO, Franco Negron.
Advertisement
ApiJect Systems, an injectable technology company, announced on Jan. 28, 2021 that it has appointed a new Leadership Advisory Board to join the company’s co-founder and chairman, Jay Walker, and company CEO, Franco Negron.
"ApiJect is indeed privileged to welcome its first members of our Leadership Advisory Board,” Negron said in a company press release. “We see this board as an essential part of our company's mission to be world leaders in the technological advancement of injectable devices. These are individuals who dream big and seek aggressive change in global and US public health."
The Leadership Advisory Board members include:
- Professor Heidi J. Larson, PhD, director of The Vaccine Confidence Project, professor of Anthropology, Risk, and Decision Science, London School of Hygiene and Tropical Medicine; clinical professor, Global Health, University of Washington, Seattle, WA
- Dr. Regina M. Benjamin, MD, family physician founder of Bayou La Batre Rural Health Clinic
- Dr. Edward Kelley, chief global health officer for ApiJect Research Foundation
- Dr. Michael J. Free, OBE, former vice-president for Technology at PATH
- Rueben M. Stokes, former vice president of Global Diversity and Inclusion for Thermo Fisher Scientific, and former corporate senior executive in Diversity, Equity, and Inclusion
- Dr. Marietta Vázquez, MD, professor, Yale University School of Medicine, attending, Yale Pediatric Primary Care Center.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5